EIF4E and prostate carcinoma: Specifically, AT-I was shown to overcome eIF4E-mediated resistance in prostate cancer by inhibiting the Hsp27/eIF4E pathway, thereby enhancing the chemosensitizing effects of cabozantinib [73].